By David Tuller, DrPH On January 10th, the following information was announced in a press release: Mahana Therapeutics, a digital therapeutics company reimagining the treatment of chronic diseases, today announced that the Company has entered into a licensing and collaboration agreement with King’s College London, a leading research university and ...

By David Tuller, DrPH Had things gone as planned, the PACE trial should have been able to serve as proof that so-called medically unexplained symptoms (MUS), in this case what the investigators referred to as chronic fatigue syndrome--could be successfully treated with psychological and behavioral therapies. The Lancet published the ...

By David Tuller, DrPH Last October, I gave a talk in Oxford (not AT Oxford) about the dung-heap known as the Lightning Process trial which was published in 2017 in Archives of Disease in Childhood, a BMJ journal. The study's full name: "Clinical and cost-effectiveness of the Lightning Process in addition ...

By David Tuller, DrPH Since 2008, the National Health Service (NHS) in England has been rolling out a program known as Improving Access to Psychological Therapies (IAPT). Initially focused on patients with mental health issues like depression and anxiety disorders, IAPT was then expanded to include those who are also ...

By David Tuller, DrPH In the UK, leading researchers are preparing to submit an application for a large genetic study to two major funding agencies. The project is being led by Professor Chris Ponting of the University of Edinburgh, who is also vice chair of the CFS/ME Research Collaborative, and ...